DVAX
Price
$9.70
Change
+$0.34 (+3.63%)
Updated
Sep 16 closing price
Capitalization
1.1B
43 days until earnings call
ELAN
Price
$18.89
Change
+$0.26 (+1.40%)
Updated
Sep 17, 11:09 AM (EDT)
Capitalization
9.26B
55 days until earnings call
Interact to see
Advertisement

DVAX vs ELAN

Header iconDVAX vs ELAN Comparison
Open Charts DVAX vs ELANBanner chart's image
Dynavax Technologies
Price$9.70
Change+$0.34 (+3.63%)
Volume$1.79M
Capitalization1.1B
Elanco Animal Health
Price$18.89
Change+$0.26 (+1.40%)
Volume$8.83K
Capitalization9.26B
DVAX vs ELAN Comparison Chart in %
Loading...
DVAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ELAN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DVAX vs. ELAN commentary
Sep 17, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DVAX is a Hold and ELAN is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 17, 2025
Stock price -- (DVAX: $9.70 vs. ELAN: $18.63)
Brand notoriety: DVAX: Not notable vs. ELAN: Notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: DVAX: 112% vs. ELAN: 62%
Market capitalization -- DVAX: $1.1B vs. ELAN: $9.26B
DVAX [@Pharmaceuticals: Generic] is valued at $1.1B. ELAN’s [@Pharmaceuticals: Generic] market capitalization is $9.26B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $64.82B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.89B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DVAX’s FA Score shows that 0 FA rating(s) are green whileELAN’s FA Score has 0 green FA rating(s).

  • DVAX’s FA Score: 0 green, 5 red.
  • ELAN’s FA Score: 0 green, 5 red.
According to our system of comparison, ELAN is a better buy in the long-term than DVAX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DVAX’s TA Score shows that 3 TA indicator(s) are bullish while ELAN’s TA Score has 3 bullish TA indicator(s).

  • DVAX’s TA Score: 3 bullish, 5 bearish.
  • ELAN’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, both DVAX and ELAN are a bad buy in the short-term.

Price Growth

DVAX (@Pharmaceuticals: Generic) experienced а -2.22% price change this week, while ELAN (@Pharmaceuticals: Generic) price change was -0.69% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +26.88%. For the same industry, the average monthly price growth was +27.55%, and the average quarterly price growth was +63.56%.

Reported Earning Dates

DVAX is expected to report earnings on Oct 30, 2025.

ELAN is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+26.88% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ELAN($9.26B) has a higher market cap than DVAX($1.1B). DVAX has higher P/E ratio than ELAN: DVAX (54.60) vs ELAN (21.17). ELAN YTD gains are higher at: 53.840 vs. DVAX (-24.041). ELAN has higher annual earnings (EBITDA): 1.45B vs. DVAX (-34.26M). DVAX has more cash in the bank: 614M vs. ELAN (539M). DVAX has less debt than ELAN: DVAX (285M) vs ELAN (4.21B). ELAN has higher revenues than DVAX: ELAN (4.48B) vs DVAX (316M).
DVAXELANDVAX / ELAN
Capitalization1.1B9.26B12%
EBITDA-34.26M1.45B-2%
Gain YTD-24.04153.840-45%
P/E Ratio54.6021.17258%
Revenue316M4.48B7%
Total Cash614M539M114%
Total Debt285M4.21B7%
FUNDAMENTALS RATINGS
DVAX vs ELAN: Fundamental Ratings
DVAX
ELAN
OUTLOOK RATING
1..100
5653
VALUATION
overvalued / fair valued / undervalued
1..100
70
Overvalued
93
Overvalued
PROFIT vs RISK RATING
1..100
80100
SMR RATING
1..100
9579
PRICE GROWTH RATING
1..100
8640
P/E GROWTH RATING
1..100
9790
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

DVAX's Valuation (70) in the Biotechnology industry is in the same range as ELAN (93) in the Agricultural Commodities Or Milling industry. This means that DVAX’s stock grew similarly to ELAN’s over the last 12 months.

DVAX's Profit vs Risk Rating (80) in the Biotechnology industry is in the same range as ELAN (100) in the Agricultural Commodities Or Milling industry. This means that DVAX’s stock grew similarly to ELAN’s over the last 12 months.

ELAN's SMR Rating (79) in the Agricultural Commodities Or Milling industry is in the same range as DVAX (95) in the Biotechnology industry. This means that ELAN’s stock grew similarly to DVAX’s over the last 12 months.

ELAN's Price Growth Rating (40) in the Agricultural Commodities Or Milling industry is somewhat better than the same rating for DVAX (86) in the Biotechnology industry. This means that ELAN’s stock grew somewhat faster than DVAX’s over the last 12 months.

ELAN's P/E Growth Rating (90) in the Agricultural Commodities Or Milling industry is in the same range as DVAX (97) in the Biotechnology industry. This means that ELAN’s stock grew similarly to DVAX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DVAXELAN
RSI
ODDS (%)
Bullish Trend 1 day ago
86%
Bearish Trend 1 day ago
71%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
75%
Bearish Trend 1 day ago
73%
Momentum
ODDS (%)
Bearish Trend 1 day ago
69%
Bullish Trend 1 day ago
62%
MACD
ODDS (%)
N/A
Bearish Trend 1 day ago
69%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
76%
Bearish Trend 1 day ago
75%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
73%
Bullish Trend 1 day ago
66%
Advances
ODDS (%)
N/A
Bullish Trend 10 days ago
62%
Declines
ODDS (%)
Bearish Trend 3 days ago
78%
Bearish Trend 8 days ago
73%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 1 day ago
76%
Aroon
ODDS (%)
Bearish Trend 1 day ago
72%
Bullish Trend 1 day ago
69%
View a ticker or compare two or three
Interact to see
Advertisement
DVAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ELAN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SPMQX6.050.03
+0.50%
Invesco SteelPath MLP Income R5
SPIIX107.28N/A
N/A
SEI S&P 500 Index I (SIMT)
STRGX62.57N/A
N/A
Sterling Capital MdCp Relatv Val Instl
MOSZX9.93N/A
N/A
MassMutual Overseas I
RLBEX38.56-0.01
-0.03%
American Funds American Balanced R4

DVAX and

Correlation & Price change

A.I.dvisor indicates that over the last year, DVAX has been loosely correlated with ACET. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if DVAX jumps, then ACET could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DVAX
1D Price
Change %
DVAX100%
+3.63%
ACET - DVAX
39%
Loosely correlated
+1.36%
SNDL - DVAX
35%
Loosely correlated
N/A
ALKS - DVAX
33%
Poorly correlated
+3.28%
ESPR - DVAX
32%
Poorly correlated
-0.36%
BCRX - DVAX
32%
Poorly correlated
+0.65%
More